CONSIDERATIONS TO KNOW ABOUT ABT-046

During the multiday, many-dose arm, baseline microbiota was equivalent among subjects that been given ibezapolstat when compared with vancomycin. At Day ten of dosing, differential abundance Evaluation and β-range demonstrated a definite distinction between the microbiome in subjects specified vancomycin in comparison with either dose of ibezapols